Investors holding CARE11 woke up on July 15 to find their units valued at 36% less than the previous day's close—dropping from R$ 3.20 to R$ 2.05, with an intraday low of R$ 1.86. There was no market announcement, no material fact filing, and no explanation from the asset manager.
This report answers the three questions every unitholder is asking right now: (1) what caused the drop? (2) does the 5-for-1 reverse split explain anything? and (3) what is this fund actually worth? No beating around the bush, backed by numbers and a fair price range at the end.
The Numbers Behind the Drop
Trading volume on July 15 reached roughly 60 times the fund's normal daily turnover, which typically ranges between 200 and 3,000 units per session. Since the drop, the unit price has staged an erratic recovery: R$ 2.26, then R$ 2.22, R$ 2.23, R$ 2.35, and R$ 2.50 today. It is a recovery, but still far below the R$ 3.20 level it started from.
Question 1: What Caused the Drop?
An honest answer starts with what did not happen: there was no market announcement, no material fact filing, and no public news to justify the sell-off. The asset manager, Zion, and the administrator, Mérito DTVM, released nothing that day.
The key detail is that this pattern has happened before. In May 2026, the B3 stock exchange itself sent an inquiry to the administrator questioning atypical price volatility—and the response was that the manager "had no knowledge of any fact that would justify" the movement. During that episode, the unit price fell from R$ 3.70 to R$ 3.06. In July, the script repeated itself, only with more force.
The structural explanation lies in the fund's negligible liquidity. CARE11 has a shrinking unitholder base (down from 11,759 to approximately 6,811) and severe concentration: retail unitholders account for barely 0.03% of the tradeable float, while virtually all the capital (99.74%) rests in the hands of a few large holders. In such a thin order book, a single sizeable sell order triggers an avalanche.
Consider the math: if normal turnover is 200 to 3,000 units per day and someone puts 64,231 units up for sale, there are simply not enough buyers to absorb that volume without crashing the price. The price falls until it finds someone willing to buy—and in this fund, that clearing point sat all the way down at R$ 1.86.
The most probable reading, therefore, is the exit of a significant unitholder, unaccompanied by any public news. It takes no scandal to drop a fund like this by 36%—just an impatient seller in a market devoid of buyers.
Question 2: Does the 5-for-1 Reverse Split Explain Anything?
Many people are confusing the July drop with the 5-for-1 reverse split the fund carried out in February 2026—confirmed by the ClubeFII community (users such as dogaum, Mark66, and GaldiSLZ reported the correction). It is worth separating these two matters clearly.
A reverse split consolidates units: in a 5-for-1 ratio, every 5 units became 1. An investor holding 2,000 units now holds 400. Conversely, the price of each unit is multiplied by 5. This is a purely accounting operation—the total value of an investor's position does not change. Only the unit count and unit price shift.
This explains the discrepancy in data still circulating:
| Document | Unit Count | Book Value per Unit |
|---|---|---|
| 2025 Annual Report (pre-split) | 35.8 million | R$ 6.94 |
| Mérito DTVM Reports 2026 (post-split) | 7.2 million | R$ 34.49 |
This represents the exact same equity, merely expressed across different unit bases (35.8M ÷ 5 ≈ 7.2M; R$ 6.94 × 5 ≈ R$ 34.49). The current price of R$ 2.50 is already the post-split quotation.
The central point: the July drop has NOTHING to do with the reverse split. The split occurred in February and is neutral to the fund's equity value. What it does is fuel confusion—older reports with different figures still circulate, leaving unitholders uncertain about the correct baseline. But data confusion does not drive down prices; selling into a thin order book does.
Question 3: What Is It Actually Worth?
Here is the question that truly matters. The book value per unit of R$ 34.49 is the accounting net asset value (NAV)—what the fund claims to be worth on its balance sheets. But this figure does not reflect what the assets would fetch on a free market, primarily due to the composition of the portfolio.
Roughly 63% of the fund's equity is tied up in a 19.92% stake in Cortel Holding S.A.—a privately held company whose shares are not traded on an exchange. This asset is valued via appraisal report (using a discounted cash flow FCFF/WACC methodology, known as "Level 3" fair value, the accounting category for assets without observable market prices). There is no immediate buyer: Cortel's IPO, mandated to XP in 2021, was canceled. In other words, the R$ 157.5 million valuation attributed to Cortel is a model-based estimate, not a check you can cash tomorrow.
A serious investor will not pay book value for an illiquid asset—they apply haircuts to reflect the difficulty of selling. Below is a conservative re-evaluation of the fund's equity:
| Asset | Book Value | Haircut | Adjusted Value |
|---|---|---|---|
| Cortel Equity (63% of NAV) | R$ 157.5M | 75% (illiquidity) | R$ 39M |
| Morumby Burial Plots (28%) | R$ 70.1M | 50% (slow sales) | R$ 35M |
| Receivables (7%) | R$ 17.9M | 10% | R$ 16M |
| Cash / Fixed Income (2%) | R$ 3.4M | 0% | R$ 3.4M |
| Adjusted NAV | R$ 248.9M | — | ~R$ 93M |
Dividing the adjusted NAV by the 7.2 million units yields a conservative value of approximately R$ 12.90 per unit. In a pessimistic scenario, where Cortel takes a 90% haircut (virtually acknowledging that the equity holds little value), the adjusted equity falls to roughly R$ 58 million—or R$ 8.00 per unit.
What this reveals: the current price of R$ 2.50 sits below even the most pessimistic scenario (R$ 8.00). The market is pricing the fund as if Cortel were worth virtually zero while still factoring in significant losses on the burial plots. That may be an overreaction. Even under the worst-case scenario modeled here, there is a theoretical upside of more than 3x—though with no defined timeline and zero income along the way.
The Fair Price Range
Speculative Fair Range: R$ 3.00 – R$ 5.00 per unit
This range reflects a steep discount to the conservative adjusted NAV (R$ 12.90) to compensate for extreme illiquidity, a complete lack of income, and fragile governance. But it only makes sense for a very specific investor profile—someone who:
- Accepts zero income for 5 years or more, adding to the nearly 5 years the fund has already gone without making distributions.
- Has the stomach to watch prices swing 30% to 40% in a single day without warning, as just happened.
- Understands that unlocking value (via a potential Cortel IPO, a strategic sale of the stake, or the resumption of distributions) has no set date—it could take years or may never happen.
What Should Unitholders Do?
If you already hold CARE11 and are sitting on a loss: the right decision does not depend on the price you paid. That is a sunk cost—money that is already gone, which should not anchor your choice today. The correct question is entirely different:
Would you buy CARE11 today, at R$ 2.50, knowing that: (a) the fund will not pay dividends at least through 2026; (b) it is extremely illiquid, featuring an order book where a single sale crashes the price; and (c) it suffers from fragile governance, marked by a troubled administrator transition and delayed financial statements?
- If the answer is no: the coherent choice is to exit, even if partially and despite the poor current liquidity. Holding simply because "it has fallen too much" allows a sunk cost to make decisions for you.
- If the answer is yes: then you are knowingly making a long-term speculative bet on unlocking value in Cortel. In that case, keep your position small (low sizing) and do not make additional contributions—do not throw good money after stalled money.
- If you are a new investor: avoid it. Dozens of well-managed, liquid FIIs with real yields make distributions every month. CARE11 is the exception that proves the rule of what to avoid with passive income. The temptation of looking "cheap" here is a liquidity trap.
For the Uninitiated: What Is CARE11?
The Brazilian Graveyard & Death Care Services FII is Brazil's only FII focused on the death care sector—cemeteries, crematoriums, and funeral services. Established in December 2011, it is a pioneer in its niche. The portfolio, held largely through its stake in Cortel, provides exposure to roughly 16 cemeteries, 8 crematoriums, 2 pet crematoriums, funeral agencies, and funeral plans spread across 6 states.
The sector is, in theory, defensive: an aging population ensures constant demand that is largely insulated from economic cycles. The problem is not the sector—it is that the fund has never managed to translate that stability into income for unitholders. With R$ 248 million in equity tied up almost entirely in illiquid assets, holding only R$ 3.4 million in cash, the fund has not distributed a single cent since September 2021.
The governance track record reinforces the warning: the last dividend was paid in September 2021 (R$ 0.0017 per unit), followed by a troubled administrator transition (Trustee to Mérito DTVM in July 2025), document retention by the former administrator that delayed audited 2025 financial statements, and continuous losses—a R$ 1.42 million loss in 2025 and a negative financial result of R$ 477 thousand in the first quarter of 2026, with declared dividends of R$ 0.
Conclusion
Rating: 3.0 / 10 — SELL
The problem with CARE11 is not the sector. Death care is a solid, defensive business with perpetual demand. The problem is the fund's structure: illiquid equity concentrated in a privately held company, no income for nearly 5 years, governance still stabilizing, and a shrinking unitholder base.
The 36% drop in July does not change the analysis—it confirms it. It is the exact behavior expected of an asset with negligible volume, where any significant sale turns into a price avalanche. There may be theoretical upside if Cortel unlocks value one day, but it remains a speculative bet without a timeline and without income along the way. For the vast majority of investors—those who need income, liquidity, or predictability—CARE11 remains a SELL.
